



(51) International Patent Classification:

A61K 47/51 (2017.01) C07D 401/14 (2006.01)

A61K 47/54 (2017.01) C07D 403/04 (2006.01)

A61K 47/55 (2017.01) C07D 403/12 (2006.01)

(21) International Application Number:

PCT/US2019/041413

(22) International Filing Date:

11 July 2019 (11.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/696,508 11 July 2018 (11.07.2018) US

(71) Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. [US/US]; 12902 Magnolia Drive, Tampa, Florida 33612-9497 (US).

(72) Inventors: BURNETTE, Pearl; 6308 MacLaurin Dr., Tampa, Florida 33647 (US). LAWRENCE, Nicholas J.; 16346 Heathrow Drive, Tampa, Florida 33647 (US). LAWRENCE, Harshani; 16346 Heathrow Drive, Tampa, Florida 33647 (US).

(74) Agent: CURFMAN, Christopher L. et al.; Meunier Carlin & Curfinan LLC, 999 Peachtree Street, NE, Suite 1300, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS




FIG. 1

(57) Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.



Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

30 July 2020 (30.07.2020)